Additional file 2: Table S1. of The case-crossover design via penalized regression

Results for the 30 drugs and drug groups of the EuroSCAR study, a Multinational Case–control study in Europe and Israel between 1997 and 2001 on patients with SJS/TEN [4]. Table S2. Reclassification of individual drugs by each method. Table S3. Relevant results of literature search for penalized regression used with case-crossover studies, performed on November 21st, 2015. Figure S1. Deviance (−2 × log-likelihood) of the lasso for different values of λ using 10-fold cross-validation. Figure S2. Sensitivity analysis of Table 2a. (DOCX 121 kb

Conditions represented from the “other skin and subcutaneous diseases” Global Burden of Diseases category in the NIAMS 2013 skin-focused grants^a (arranged in order of decreasing funding).

a<p>See reference 11.</p>b<p>Only for fiscal year 2013; total funding for all NIAMS skin categories is $73,345,407.</p

NIAMS skin funding in 2013 compared to skin disease disability scatter plot–GBD 2010 skin condition category NIAMS 2013 grant funding versus US GBD 2010 skin condition DALYs.

<p>NIAMS skin funding in 2013 compared to skin disease disability scatter plot–GBD 2010 skin condition category NIAMS 2013 grant funding versus US GBD 2010 skin condition DALYs.</p

Broad scientific themes of NIAMS 2013 skin grants in percentage.

<p>Broad scientific themes of NIAMS 2013 skin grants in percentage.</p

NIAMS skin funding in 2013 and skin disease disability bar graph—Distribution of NIAMS funding in 2013 for skin-related grants (red) compared to percent of total US GBD 2010 DALYs for each category (blue).

<p>NIAMS skin funding in 2013 and skin disease disability bar graph—Distribution of NIAMS funding in 2013 for skin-related grants (red) compared to percent of total US GBD 2010 DALYs for each category (blue).</p